ATE288751T1 - Lipidsenkende kombination, die im wesentlichen frei ist von toxischen wirkungen und nebenwirkungen der lipidsenker - Google Patents

Lipidsenkende kombination, die im wesentlichen frei ist von toxischen wirkungen und nebenwirkungen der lipidsenker

Info

Publication number
ATE288751T1
ATE288751T1 AT99830415T AT99830415T ATE288751T1 AT E288751 T1 ATE288751 T1 AT E288751T1 AT 99830415 T AT99830415 T AT 99830415T AT 99830415 T AT99830415 T AT 99830415T AT E288751 T1 ATE288751 T1 AT E288751T1
Authority
AT
Austria
Prior art keywords
lipid
lowering
essentially free
side effects
effects
Prior art date
Application number
AT99830415T
Other languages
English (en)
Inventor
Arduino Arduini
Alessandro Peschechera
Paolo Carminati
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Application granted granted Critical
Publication of ATE288751T1 publication Critical patent/ATE288751T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AT99830415T 1999-06-30 1999-06-30 Lipidsenkende kombination, die im wesentlichen frei ist von toxischen wirkungen und nebenwirkungen der lipidsenker ATE288751T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99830415A EP1064943B1 (de) 1999-06-30 1999-06-30 Lipidsenkende Kombination, die im wesentlichen frei ist von toxischen Wirkungen und Nebenwirkungen der Lipidsenker

Publications (1)

Publication Number Publication Date
ATE288751T1 true ATE288751T1 (de) 2005-02-15

Family

ID=8243483

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99830415T ATE288751T1 (de) 1999-06-30 1999-06-30 Lipidsenkende kombination, die im wesentlichen frei ist von toxischen wirkungen und nebenwirkungen der lipidsenker

Country Status (6)

Country Link
EP (1) EP1064943B1 (de)
AT (1) ATE288751T1 (de)
DE (1) DE69923670T2 (de)
DK (1) DK1064943T3 (de)
ES (1) ES2237073T3 (de)
PT (1) PT1064943E (de)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0667833B2 (ja) * 1985-11-28 1994-08-31 雪印乳業株式会社 経腸栄養剤
CA2007983C (en) * 1989-01-18 1996-12-10 Michael S. Brown Coenzyme q10 with hmg-coa reductase inhibitors
IT1293067B1 (it) * 1997-07-01 1999-02-11 Sigma Tau Ind Farmaceuti Composizione farmaceutica per il trattamento di patologie causate da alterato metabolismo lipidico

Also Published As

Publication number Publication date
DE69923670T2 (de) 2006-03-09
DK1064943T3 (da) 2005-06-06
EP1064943B1 (de) 2005-02-09
EP1064943A1 (de) 2001-01-03
DE69923670D1 (de) 2005-03-17
PT1064943E (pt) 2005-06-30
ES2237073T3 (es) 2005-07-16

Similar Documents

Publication Publication Date Title
BG105559A (en) STABLE PHARMACEUTICAL FORMULATION COMPRISING A HMG-CoA REDUCTASE INHIBITOR
DE60018100D1 (en) Polymorphe form von atorvastatin-calcium
IE970731A1 (en) Product and method for the treatment of hyperlipidemia
ATE263558T1 (de) Lipasehemmer und chitosan enthaltende pharmazeutische zusammensetzungen
ES2193337T3 (es) Utilizacion de sales de estroncio para el tratamiento de la artrosis.
CA2324283A1 (en) Pharmaceutical composition containing a statin and aspirin
FI951856A (fi) Farmaseuttinen koostumus osteoporoosin hoitamiseksi
GEP20053548B (en) Sugar-Substituted 2-Azetidinones Useful as Hypocholesterolemic Agents
PT1183228E (pt) Esteres de l-carnitina ou alcanoil l-carnitinas
ATE417617T1 (de) Mittel zur steurung der expression von il-12
WO2002011666A3 (en) Derivatives of branched-chain lipophilic molecules and uses thereof
IL162325A0 (en) Hiv integrase inhibitor compounds and pharmaceutical compositions containing the same
JP2005511619A5 (de)
MY118381A (en) Statin-carboxyalkylether combinations
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
ATE288751T1 (de) Lipidsenkende kombination, die im wesentlichen frei ist von toxischen wirkungen und nebenwirkungen der lipidsenker
EP1604658A3 (de) Pharmazeutische Zubereitung enthaltend Ibuprofen und Prochlorperazin
CA2375378A1 (en) Antilipemic combinations comprising hmg-coa reductase inhibitors and carnitines
DE60142308D1 (de) Vorbeugungs- oder heilmittel gegen endometriose
UY28729A1 (es) Composiciones hipocolesterolemiantes
MX9405371A (es) Derivado de naftilo.
CL2004001291A1 (es) Composicion farmaceutica que comprende compuestos carbociclicos y heterociclicos; y su uso para el tratamiento o profilaxis de la infeccion por influenza.
BG106918A (en) Perocess for the preparation of sodium salts of statins
WO2005058310A3 (en) Use of stating for the treatment of metabolic syndrome
MY140504A (en) Statin-mmp inhibitor combinations

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1064943

Country of ref document: EP